Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Shavonne L Teng *Department of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.ORCID 0000-0002-1045-0879
Rocco Latorre *Department of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.ORCID 0000-0003-2737-8233
Divya BhansaliDepartment of Biomedical Engineering, Columbia University, New York, NY 10027.ORCID 0000-0001-8777-3089
Parker K LewisPain Research Center, College of Dentistry, New York University, New York, NY 10010.
Rachel E PollardPain Research Center, College of Dentistry, New York University, New York, NY 10010.
Chloe J PeachDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.
Badr SokratDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.ORCID 0000-0002-5770-1858
Gokul Sriman Thanigai ArasuDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.ORCID 0009-0001-2739-6645
Tracy ChiuDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.
Paz DuranDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.ORCID 0000-0001-8729-8636
Nestor N Jimenez-VargasGastrointestinal Diseases Research Unit, Division of Gastroenterology, Queen's University, Kingston, Canada K7L 2V7.ORCID 0000-0001-6595-1884
Abby MocherniakGastrointestinal Diseases Research Unit, Division of Gastroenterology, Queen's University, Kingston, Canada K7L 2V7.
Matthew BogyoDepartment of Pathology, Stanford Medical School, Stanford University, Stanford, CA 94305.ORCID 0000-0003-3753-4412
Michael M GaspariSection of Gastroenterology, Wake Forest University School of Medicine, Winston-Salem, NC 27101.
Stephen J VannerGastrointestinal Diseases Research Unit, Division of Gastroenterology, Queen's University, Kingston, Canada K7L 2V7.
Nathalie M PinkertonPain Research Center, College of Dentistry, New York University, New York, NY 10010.ORCID 0000-0001-9325-9764
Kam W LeongDepartment of Biomedical Engineering, Columbia University, New York, NY 10027.ORCID 0000-0002-8133-4955
Brian L SchmidtDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.
Dane D JensenDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.ORCID 0000-0001-6540-2375
Nigel W BunnettDepartment of Molecular Pathobiology, College of Dentistry, New York University, New York, NY 10010.ORCID 0000-0003-3367-0644
Funding
Endosomal mechanisms signaling oral cancer painRM1DE033491 · NIDCR · NEW YORK UNIVERSITY · PI NIGEL W BUNNETT, Rajesh Khanna · 2023 to 2026
$6.4M
Targeting Endosomal Receptors for Treatment of Chronic PainR01DE029951 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2020 to 2024
$4.7M
Protease/PAR2/TRPV4 Axis and Oral Cancer PainR01DE026806 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2022
$3.9M
Endosomal Platforms for Signaling PainR01NS102722 · NINDS · NEW YORK UNIVERSITY · PI NIGEL W BUNNETT, Brian L Schmidt · 2017 to 2026
$3.4M
Trafficking-Dependent Signaling of Pain by Protease-Activated ReceptorsR01DK118971 · NIDDK · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2018 to 2021
$3.2M
Targeting bacterial proteases involved in PAR signaling to treat inflammatory bowel diseasesR01DK130293 · NIDDK · STANFORD UNIVERSITY · PI BOGYO, MATTHEW · 2021 to 2025
$2.4M
Mechanisms of Endosomal Signaling of ItchR01NS125413 · NINDS · NEW YORK UNIVERSITY · PI Dane D Jensen · 2022 to 2026
$1.9M
Department of Defense Grants W81XWH1810431Department of Defense Grants W81XWH2210239HHS | NIH | National Institute of Dental and Craniofacial Research (NIDR) R01DE026806HHS | NIH | National Institute of Dental and Craniofacial Research (NIDR) R01DE029951HHS | NIH | National Institute of Dental and Craniofacial Research (NIDR) RM1DE033491HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK118971HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK130293HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 5R01NS125413HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS102722NIDCR NIH HHS R01 DE026806NIDCR NIH HHS R01 DE029951NIDCR NIH HHS RM1 DE033491NIDDK NIH HHS R01 DK118971NIDDK NIH HHS R01 DK130293NINDS NIH HHS R01 NS102722NINDS NIH HHS R01 NS125413
6 · The paper itself
Abstract
Although many internalized G protein-coupled receptors (GPCRs) continue to signal, the mechanisms and outcomes of intracellular GPCR signaling are uncertain due to the challenges of measuring organelle-specific signals and of selectively antagonizing receptors in intracellular compartments. Herein, genetically encoded biosensors targeted to the plasma membrane and early endosomes were used to analyze compartmentalized signaling of protease-activated receptor 2 (PAR
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Nanomedicines targeting protease-activated receptor 2 in endosomes provide sustained analgesia. · full record | OpenQuestion